NasdaqGS:HSIC

Stock Analysis Report

Executive Summary

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide.

Snowflake

Fundamentals

Solid track record with excellent balance sheet.


Similar Companies

Share Price & News

How has Henry Schein's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.5%

NasdaqGS:HSIC

0.8%

US Healthcare

1.3%

US Market


1 Year Return

-22.9%

NasdaqGS:HSIC

-8.2%

US Healthcare

2.0%

US Market

HSIC underperformed the Healthcare industry which returned -8.2% over the past year.

HSIC underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

HSICIndustryMarket
7 Day4.5%0.8%1.3%
30 Day4.2%-1.5%3.9%
90 Day-9.9%-0.5%3.4%
1 Year-1.7%-22.9%-6.8%-8.2%4.2%2.0%
3 Year-0.06%-21.6%30.2%24.9%47.2%37.6%
5 Year40.1%9.9%63.6%53.9%60.5%42.9%

Price Volatility Vs. Market

How volatile is Henry Schein's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Henry Schein undervalued based on future cash flows and its price relative to the stock market?

19%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Henry Schein's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Henry Schein's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Henry Schein is good value based on earnings compared to the US Healthcare industry average.

Henry Schein is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Henry Schein is poor value based on expected growth next year.


Price Based on Value of Assets

Henry Schein is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Henry Schein expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

5.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Henry Schein's revenue is expected to grow by 2.5% yearly, however this is not considered high growth (20% yearly).

Henry Schein's earnings are expected to grow by 5.8% yearly, however this is not considered high growth (20% yearly).

Henry Schein's revenue growth is positive but not above the United States of America market average.

Henry Schein's earnings growth is positive but not above the United States of America market average.

Henry Schein's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Henry Schein is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Henry Schein performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Henry Schein's year on year earnings growth rate has been positive over the past 5 years.

Henry Schein's 1-year earnings growth exceeds its 5-year average (56% vs 0.2%)

Henry Schein's earnings growth has exceeded the US Healthcare industry average in the past year (56% vs 5.6%).


Return on Equity

Henry Schein has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Henry Schein used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Henry Schein has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Henry Schein's financial position?


Financial Position Analysis

Henry Schein is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Henry Schein's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Henry Schein's level of debt (32.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (22.6% vs 32.7% today).

Debt is well covered by operating cash flow (51.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 17.8x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 2.5x debt.


Next Steps

Dividend

What is Henry Schein's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Henry Schein's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Henry Schein's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Henry Schein has not reported any payouts.

Unable to verify if Henry Schein's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Henry Schein has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Henry Schein's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Henry Schein's salary, the management and board of directors tenure and is there insider trading?

7.7yrs

Average management tenure


CEO

Stanley Bergman (69yo)

30.7yrs

Tenure

US$6,481,739

Compensation

Mr. Stanley M. Bergman has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989. Mr. Bergman has been an Executive Director of Henry Schein, Inc. since 1982. He served a ...


CEO Compensation Analysis

Stanley's remuneration is about average for companies of similar size in United States of America.

Stanley's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

7.7yrs

Average Tenure

62.5yo

Average Age

The average tenure for the Henry Schein management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

18.3yrs

Average Tenure

65.5yo

Average Age

The average tenure for the Henry Schein board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

Henry Schein individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$1,494,78520 Jun 19
Steven Paladino
EntityIndividual
Role
Member of the Board of Directors
Executive VP
Shares20,712
Max PriceUS$72.17
SellUS$1,413,75320 Jun 19
Gerald Benjamin
EntityIndividual
Role
Member of the Board of Directors
Executive VP
Shares19,630
Max PriceUS$72.02
SellUS$249,14014 Jun 19
E. Rekow
EntityIndividual
Shares3,500
Max PriceUS$71.21
SellUS$124,74813 Jun 19
Paul Brons
EntityIndividual
Shares1,758
Max PriceUS$70.96
SellUS$64,88813 Mar 19
Philip Laskawy
EntityIndividual
Role
Lead Director
Lead Director
Shares1,084
Max PriceUS$59.86
SellUS$212,30706 Mar 19
Philip Laskawy
EntityIndividual
Role
Lead Director
Lead Director
Shares3,591
Max PriceUS$59.12
BuyUS$121,19026 Feb 19
Anne Margulies
EntityIndividual
Shares2,000
Max PriceUS$60.60
SellUS$626,37312 Dec 18
Michael Ettinger
EntityIndividual
Shares7,425
Max PriceUS$84.36
SellUS$5,955,99707 Dec 18
Stanley Bergman
EntityIndividual
Role
Chief Executive Officer
Executive Chairman & CEO
Shares69,000
Max PriceUS$89.07
SellUS$1,901,16704 Dec 18
Steven Paladino
EntityIndividual
Role
Member of the Board of Directors
Executive VP
Shares21,110
Max PriceUS$90.06
SellUS$738,65503 Dec 18
David McKinley
EntityIndividual
Shares8,321
Max PriceUS$88.77

Ownership Breakdown


Management Team

  • Stanley Bergman (69yo)

    Executive Chairman & CEO

    • Tenure: 30.7yrs
    • Compensation: US$6.48m
  • Steven Paladino (62yo)

    Executive VP

    • Tenure: 26.8yrs
    • Compensation: US$2.65m
  • James Breslawski (65yo)

    Vice Chairman & President

    • Tenure: 1.3yrs
    • Compensation: US$2.75m
  • Gerald Benjamin (66yo)

    Executive VP

    • Tenure: 25yrs
    • Compensation: US$2.65m
  • Mark Mlotek (63yo)

    Executive VP

    • Tenure: 24yrs
    • Compensation: US$2.48m
  • Walter Siegel (59yo)

    Senior VP & General Counsel

    • Tenure: 5.9yrs
  • Gerard Meuchner (56yo)

    Chief Global Communications Officer & VP

    • Tenure: 7.6yrs
  • Carolynne Borders

    Vice President of Investor Relations

    • Tenure: 6.8yrs
  • Ronald South

    Chief Accounting Officer & VP of Corporate Finance

    • Tenure: 0yrs
  • Chris Pendergast (56yo)

    Senior VP & CTO

    • Tenure: 1.4yrs

Board Members

  • Phil Laskawy (78yo)

    Lead Director

    • Tenure: 7.7yrs
    • Compensation: US$314.40k
  • Stanley Bergman (69yo)

    Executive Chairman & CEO

    • Tenure: 30.7yrs
    • Compensation: US$6.48m
  • Steven Paladino (62yo)

    Executive VP

    • Tenure: 26.8yrs
    • Compensation: US$2.65m
  • James Breslawski (65yo)

    Vice Chairman & President

    • Tenure: 1.3yrs
    • Compensation: US$2.75m
  • Gerald Benjamin (66yo)

    Executive VP

    • Tenure: 25yrs
    • Compensation: US$2.65m
  • Mark Mlotek (63yo)

    Executive VP

    • Tenure: 24yrs
    • Compensation: US$2.48m
  • Joe Herring (63yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$291.40k
  • Louis Sullivan (86yo)

    Chairman of Medical Advisory Board

    • Tenure: 13.2yrs
    • Compensation: US$225.87k
  • Barry Alperin (79yo)

    Independent Director

    • Tenure: 23.3yrs
    • Compensation: US$308.40k
  • Brad Sheares (62yo)

    Independent Director

    • Tenure: 9.7yrs
    • Compensation: US$282.18k

Company Information

Henry Schein, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Henry Schein, Inc.
  • Ticker: HSIC
  • Exchange: NasdaqGS
  • Founded: 1932
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$9.536b
  • Shares outstanding: 148.26m
  • Website: https://www.henryschein.com

Number of Employees


Location

  • Henry Schein, Inc.
  • 135 Duryea Road
  • Melville
  • New York
  • 11747
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSICNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1995
HS2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1995
HSICWBAG (Wiener Boerse AG)YesCommon StockATEURNov 1995

Biography

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 23:44
End of Day Share Price2019/09/13 00:00
Earnings2019/06/29
Annual Earnings2018/12/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.